Table 4.
No. of Patients |
Dose (mg/m2) |
Cpmax (ng/mL) | AUC0–12 h (µg × h/mL) | Decrease in Retinol | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
4-HPR | 4-MPR | 4-HPR | 4-MPR | |||||||||
Value | SD | Value | SD | Value | SD | Value | SD | % | SD | Range | ||
26 | 600 | 832 | 360 | 232 | 125 | 5.84 | 2.47 | 1.64 | 0.93 | 45.83 | 10.05* | 25%–67% |
4 | 900 | 1213 | 261 | 337 | 113 | 8.60 | 2.17 | 2.45 | 0.83 | 50.33 | 5.03† | 45%–55% |
NOTE. Cpmax and AUC0–12 h reflective of 600 or 900 mg/m2 single administration. Retinol levels were assessed at baseline and 24 hours after fenretinide was first administered.
Abbreviations: 4-MPR, N-(4-methoxyphenyl)-retinamide; Cpmax, peak concentration; AUC, area under the concentration-time curve; SD, standard deviation.
n = 23
n = 3.